Evommune, Inc. (EVMN) Financial Statements
Evommune, Inc. (EVMN) reported trailing twelve-month revenue of $10.0M (up 85.7% year on year) and net income of -$94.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$74.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EVMNEvommune, Inc.Follow EVMN — free
—
Price chart with a free account
- Market cap
- 185.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Dec, in 46 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 7.0 | 13.0 | 10.0 | |
| Research & development | 64.2 | 74.0 | 83.8 | |
| Operating income | -70.0 | -81.1 | -101.9 | |
| Pre-tax income | -66.8 | -68.9 | -94.7 | |
| Income tax | — | 0.0 | 0.0 | |
| Net income | -66.8 | -68.9 | -94.7 | |
| Diluted EPS ($) | -45.29 | -11.22 | -2.61 | |
| Diluted shares (mn) | 1.5 | 6.1 | — |
USD millions · SEC XBRL
Evommune, Inc. — questions
- What is Evommune, Inc.'s revenue?
- $10.0M over the twelve months to 2026-06-30, up 85.7% year on year, from its 10-Q and 10-K filings.
- What is Evommune, Inc.'s net income?
- -$94.7M over the twelve months to 2026-06-30.
- What is Evommune, Inc.'s free cash flow?
- -$74.7M over the twelve months to 2026-06-30.
- What are Evommune, Inc.'s diluted earnings per share?
- $-2.61 over the twelve months to 2026-06-30.
Every figure on this page comes from Evommune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.